GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 220 Note 3 (c): Consequent to the approval of the shareholders, the Parent company on September 30, 2021, has acquired the assets and liabilities associated with the vaccine business of GlaxoSmithKline Asia Private Limited. The Group has accounted the acquisition in accordance with Appendix C to IND AS 103 being business combination of entities under common control. Accordingly, the financial information in respect of prior periods has been restated for the acquisition as if the business combination has occurred from the beginning of preceding periods. Capital work-in-progress: ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Opening Balance 13,21.43 120,12.15 Additions 35,35.92 20,95.67 Less: Capitalisation (18,07.14) (57,62.89) Asset held for sale (Refer Note 3(b) above) - (70,23.50) Closing Balance 30,50.21 13,21.43 ( ` in lakhs ) As at March 31, 2022 Less than 1 year 1-2 years 2-3 years More than 3 years Total Capital work-in-progress 19,21.09 9,46.59 1,23.82 58.71 30,50.21 As at March 31, 2021 Less than 1 year 1-2 years 2-3 years More than 3 years Total Capital work-in-progress 7,11.42 5,00.33 99.74 9.94 13,21.43 Project is overdue or has exceeded its cost compared to its original plan ( ` in lakhs ) As at March 31, 2022 Less than 1 year 1-2 years 2-3 years More than 3 years Total Capital work-in-progress 12,11.72 - 58.71 - 12,70.43 ( ` in lakhs ) As at March 31, 2021 Less than 1 year 1-2 years 2-3 years More than 3 years Total Capital work-in-progress 5,76.17 2,44.03 36.07 - 8,56.27